SOTIO

November is both Pancreatic Cancer Awareness Month and Stomach Cancer Awareness Month – two cancer types greatly in need of new treatment options. We’re advancing a clinical trial of #ADC SOT109 as a potential therapeutic option for gastrointestinal cancers. SOT109 targets CDH17, a protein abundantly expressed in GI cancers, including CRC, stomach, pancreatic, and esophageal cancers.

We remain committed to advancing innovative therapies with the potential to make a difference for patients.
#PancreaticCancerAwareness #StomachCancerAwareness #Oncology #Cancer

Our Chief Scientific Officer Amy Jensen-Smith has been recognized by @HealthTechRPT as one of this year’s Top Women Leaders in Biotech and Life Sciences! Since joining SOTIO more than five years ago, Amy has played an instrumental role in advancing our scientific vision and pipeline. From leading global discovery and preclinical research to helping guide our next-generation #ADCs toward clinical development, her scientific leadership continues to shape what’s ahead for SOTIO. Congratulations, Amy, on this well-deserved recognition!

See the report: bit.ly/4sHL37C

We’re on the ground at #SITC26 and looking forward to presenting the first clinical data on SOT201, our PD-1 targeting IL-15 immunocytokine. Interim data from the Phase 1 VICTORIA-01 clinical trial show early evidence of durable antitumor activity with SOT201, including responses in patients whose #cancer had progressed after checkpoint inhibitor therapy.

Read more in today’s press release: sotio.com/news-publicati…

@sitcancer
#CancerImmunotherapy #Immunocytokine #DrugDevelopment #ClinicalTrials

This month we are heading to @EBDgroup’s #BIOEurope2026 in Germany to connect with potential collaborators and explore opportunities to advance our oncology pipeline.

With two next-generation ADC programs in development for solid tumors, we’re interested in conversations around partnering, licensing, and investment with companies and investors focused on bringing differentiated cancer therapies to patients.

If you would like to arrange a meeting with our BD team, please reach out to partnering@sotio.com.
#BiotechPartnering #ADC #Oncology

Next week at #SITC2026 we will present initial data from VICTORIA-01, our Phase 1 study evaluating SOT201 in patients with advanced or metastatic solid tumors. SOT201 is a novel cis-acting immunocytokine, combining IL-15 superagonist and anti-PD-1 activity in order to stimulate tumor specific T cells. We’re looking forward to engaging with the #CancerImmunotherapy community and sharing these promising data.
@sitcancer #Immunotherapy